Deferasirox BID (Twice a Day) in Transfusion Dependent Thalassemia Patients With Inadequate Response to High Doses
Status:
Withdrawn
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
This is an open label, single arm, and multicenter study. The study will include the
following phases. A screening phase which lasts for 4 weeks to determine patient eligibility.
This phase will be followed by a 24 week Open label treatment phase. The study treatment is
defined as deferasirox 20mg/kg BID 9Twice a day). Serum Ferritin Levels and MRI (Magmetic
Resonance Imaging) LIC (Liver Iron Concentration) will be measured to evaluate the response
to BID.